Matthew Daniels

Matthew Daniels

Company: Accent Therapeutics

Job title: Associate Director


DHX9 Inhibitors as Novel Therapeutic Modalities in MSI-High Cancers 3:00 pm

DHX9 is an RNA helicase with important roles in replication, transcription, translation, RNA splicing and RNA processing Microsatellite instable high (MSI-high) cancer cell lines are selectively dependent on DHX9 activity Potent inhibitors of DHX9 have been identified that show antiproliferative activity in MSIhigh cancer models in vitro and in vivoRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.